SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical
Ionis Pharmaceuticals (IONS)
An SI Board Since May 1996
Posts SubjectMarks Bans Symbol
4676 121 0 IONS
Emcee:  Keith Fauci Type:  Unmoderated
Introduction Market Data Compact
Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):
ReplyMessage PreviewFromRecsPosted
3426As far as I'm aware, Isis Innovation ("Oxford University's technolonigel bates-5/7/2003
3425>>We have had a nice rally. Do you have any opinion on why on this?<&tuck-5/7/2003
3424Webcast Alert: Isis Pharmaceuticals Announces First Quarter Financial Results Webob zagorin-5/5/2003
3423Studies Demonstrate Potential Clinical Utility Of siRNA in Ophthalmic Disease Fnigel bates-5/5/2003
3422Also, take a look at the action of erstwhile partner, Hybridon (hybn).bob oserin-5/2/2003
3421jmho, several reasons oversold based on speculation that their antisense platfobob zagorin-5/1/2003
3420Bob We have had a nice rally. Do you have any opinion on why on this? mjMJ-4/30/2003
3419Isis Pharmaceuticals Achieves Milestone in Antisense Drug Discovery Collaboratiobob zagorin-4/21/2003
3418Isis Pharmaceuticals Initiates Additional Phase II Clinical Trial Of Alicaforsenbob zagorin-4/8/2003
3417OncoGenex Technologies expands the clinical evaluation of lead antisense drug bob zagorin-4/7/2003
3416Sorry I cannot answer your question. I have been out of the stock for some timeKeith Fauci-4/5/2003
3415didn't see any mention of affinitak and haven't had time to listen to thbob zagorin-4/2/2003
3414SEQUENOM and Isis Pharmaceuticals Collaborate to Discover Genetic Variation in Abob zagorin-4/2/2003
3413CARLSBAD, Calif., April 2 /PRNewswire-FirstCall/ -- Isis Pharmaceuticals, Inc. (nigel bates-4/2/2003
3412Isis Pharmaceuticals Announces Live Webcast to Provide General Corporate Update bob zagorin-3/19/2003
3411Sorry for the confusion. I agree that the ones who didn't complete treatmenmjsolomon-3/18/2003
3410Bob The life extension given to these patients was minimal---if I understand---MJ-3/18/2003
3409i don't understand your logic. could you try again. to me it says most of thbob zagorin-3/18/2003
3408I'm bothered by the analysis that indicates that patients who completed treamjsolomon-3/18/2003
3407Cancer Drug by Isis and Lilly Fails in Big Clinical Trial "<i>... CySemiBull-3/18/2003
3406Motley Fool: Isis Cancer Drug Disappoints Monday March 17, 12:20 pm ET By JefSemiBull-3/17/2003
3405Antisense Still Makes Sense Matthew Herper, 03.17.03, 12:05 PM ET NEW YORK -SemiBull-3/17/2003
3404haven't had a chance to listen to the call yet but my quick take is that manbob zagorin-3/17/2003
3403Any possibility for ISIS? Is it a buy here? They still have cash-----but needMJ-3/17/2003
3402CARLSBAD, Calif. and INDIANAPOLIS, March 17 /PRNewswire-FirstCall/ -- Isis Pharmnigel bates-3/17/2003
Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):
HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2026 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News